Presenting Companies
The world declared a war on opioids two decades ago. It has not worked very well. This is due to the inability of existing or emerging therapies to adequately treat severe pain. At Aether, we are developing a novel neuromodulator that suppresses the dependence signals of an opioid without interfering with analgesic function. Our Phase 2A study is designed to demonstrate POC for two potential product profiles: 1) a non-addictive pain medicine with opioid equivalent analgesia without risk of dependence; and 2) a treatment for Opioid Use Disorders.
AGED Diagnostics is developing an accurate, noninvasive blood test to diagnose MASH and stage liver fibrosis. In 2025, approximately 25 million Americans had MASH, yet only 3% were diagnosed, contributing to more than $90 billion in avoidable downstream healthcare spending. AGED recently completed a clinical verification study involving more than 300 patients and demonstrated greater than 95% accuracy in both diagnosing MASH and staging liver fibrosis. With two FDA-approved therapeutics now available for MASH, accurate diagnostics that identify patients and guide treatment have become increasingly urgent.
Allogenetics is advancing an ex vivo gene therapy designed as a one-time treatment to modify donor organs, with the goal of reducing and potentially eliminating the need for lifelong immunosuppression. Our proprietary technology platform enables a calibrated knockdown of cell-surface antigen presentation (MHC class I and II) to evade graft rejection while retaining full immune competence. Building on compelling proof-of-concept in animal models, we are advancing our novel organ-agnostic approach toward human clinical trials, starting with lung and kidney grafts. Our mission is to enable longer and healthier lives for transplant patients by improving graft survival and patient quality of life.
Alveolus Bio is a clinical-stage-focused biotechnology company developing first-in-class inhaled biotherapeutics for serious respiratory diseases. Its proprietary resMIT platform is designed to formulate and deliver viable biotherapeutics directly to the distal lung, enabling localized treatment of pulmonary inflammation and dysbiosis. The company’s lead program, AB1000, is being advanced for COPD and is supported by published preclinical data, FDA pre-IND feedback, and an integrated CMC and manufacturing program. Alveolus is progressing the program toward IND and first-in-human clinical development while building additional pipeline opportunities in respiratory disease.
Avails Medical is a commercial-stage diagnostics company building the sensing and data layer for microbiology. Its proprietary all-electrical biosensor platform continuously measures microbial metabolism, transforming biological growth into real-time, actionable data. Avails’ first product, eQUANT, is FDA 510(k)-cleared and enables conventional antimicrobial susceptibility testing up to 24 hours sooner, while its next product, eAST, is being developed to deliver rapid phenotypic AST directly from positive blood cultures in approximately six hours. The same sensing platform has potential applications beyond clinical microbiology, including pharmaceutical quality control, bioprocessing, food safety, and other areas requiring real-time microbial intelligence.
We are developing CAMV-01, a drug candidate that does not kill cancer cells but stimulates the immune system to attack and kill cancer. Many cancers over-produce vasoactive intestinal peptide (VIP). VIP binds VPAC1 and VPAC2 receptors on T cells, NK cells and myeloid cells and shuts down their anti-tumor activity, so the tumor grows unopposed. CAMV-01 blocks VIP at both receptors. PD-1 antibodies release one brake on one cell type; VIP blockade lifts T, NK and myeloid suppression at once. The AML market is crowded, however we target a form of AML for which there is no approved effective medicine. Our first indication is relapsed or refractory TP53-mutated AML. Venetoclax plus azacitidine is the standard of care for patients who cannot take intensive chemotherapy. That regimen produces remissions in about 40% of patients, lasting under six months.
Causeway Therapeutics is a clinical-stage biotech pioneering first-in-class microRNA therapies to treat tendon disease. Our lead program, TenoMiR, is a locally-delivered microRNA-29a mimic that recently completed Phase 2 in Lateral Epicondylitis, achieving promising results across all three key domains in tendinopathy – improvement in pain, function and structure. By restoring miR-29a activity at the site of injury, our approach targets the underlying collagen dysregulation, rather than simply managing symptoms. Tendinopathy presents an untapped $50BN total addressable market, of which TenoMiR targets $20BN at peak, with first-mover advantage in a space with zero approved therapies targeting tendon healing. Causeway is now raising a Series A to advance this program toward pivotal trials and expand our microRNA platform into additional tendon indications, including Rotator Cuff Tendinopathy.
Ceretype has pioneered the integration of fMRI into therapeutic applications in neuropsychiatry. Our uniquely scalable platform makes targeted biomarkers accessible, delivering actionable insights for our pharma/biotech partners. Our decades of expertise across neuromedicine, brain imaging, and industry processes enables innovations that will ultimately transform patient care.
​Codex Labs is a science-driven plant-biotechnology company focused on the discovery and development of botanical solutions for skin and gut-microbiome-related conditions. Its technology platform investigates plant-derived bioactives and their potential to support the interconnected skin, gut, brain, and microbiome systems, with an initial focus on eczema, acne, rosacea, and psoriasis. The company’s botanical drug development strategy is complemented by clinically evaluated over-the-counter (OTC) skincare and dietary supplements, as well as an evolving telehealth model designed to support personalized care through skin-gut-brain-microbiome diagnostics. Together, these capabilities are intended to accelerate the translation of botanical science into accessible, evidence-based health solutions.
FluidForm Bio™ is creating living human tissue for better treatment of disease. Our patented FRESH™ technology is a revolutionary platform designed to build tissue using cells, proteins, and nothing else. Through partnerships with top life science companies, our technology has been validated to produce the highest quality tissue in a variety of applications.  We deliver human tissue that is indistinguishable from the real thing by integrating breakthrough innovations in 3D printing, computational and synthetic biology, AI, and advanced materials science. Our living tissue will offer therapies to countless patients who deserve better treatment options. 
Geneius is developing an adoptive cell therapy technology that is designed to selectively unleash the patient’s immune response to cancer, and may do so in a more robust way than currently available approaches.
Geneius’ platform re-educates the patient’s own T cells to be responsive to overlooked antigens to deliver a specific and durable immune response that is less available to immune evasion. Planned applications will be for blood cancers and all solid tumors.
General Oncology is a biopharmaceutical company whose first-in-class investigational treatment GO-4 for stage IV pancreatic cancer significantly outperforms daraxonrasib in vitro and demonstrated a promising signal of efficacy in a phase 1 trial, with 2 of 4 evaluable patients at higher doses remaining free of disease at 54 and 37 months. GO-4 is given in only two cycles approximately six weeks apart, with patients receiving no further cancer therapy unless there is disease progression. Data were presented at ESMO Congress 2025. The novel redox-based mechanism of action is designed to remove drug resistance to melphalan without causing chronic toxicity to patients, allowing clinically relevant doses of melphalan—which generally have no long-term side effects—to achieve a marked potentiation in cancer cell killing while simultaneously activating other pathways of cancer cell destruction. The company was founded after its Chief Scientific and Medical Officer pioneered a new treatment approach for his sister’s pancreatic cancer; she is now more than 14 years cancer-free, having received only two cycles of therapy after surgical resection.
Hedonia - The only patented, non-prescription 3-in-1 Medical Food specifically formulated for the dietary management of depression and to help correct nutritional deficiencies associated with depression.Hedonia is not a drug, nor a supplement, taken twice daily, the One Solution Hedonia capsule contains only three key natural ingredients. Developed by world-renowned Psychiatrist and Psychopharmacologist, Dr. Alex Vuckovic, MD, Hedonia launched in December of 2024 and has been sold via Direct To Consumers and Amazon.com for the past 16 months with current plans to expand into health stores, big box retail and healthcare platforms, domestically and internationally.
Immune Propulsion is a biotechnology company developing a novel immunotherapy approach for solid tumors. The company uses enzyme-cleaved antibodies and an IgG-degrading protease platform to amplify endogenous anti-tumor immunity and enhance the activity of both natural host antibodies and approved monoclonal antibodies. The concept is rooted in historical observations of tumor regression associated with Streptococcus pyogenes infection and is designed as a simple, inexpensive intervention that does not add expected side effects. The platform is advancing toward clinical proof of concept in humans, with a veterinary program already in partnership for large-mass tumors in companion animals.
Access is the foundation. Biology is the opportunity. KIFFIK Biomedical is developing technology that enables continuous, non-invasive access to interstitial fluid (ISF), an information-rich biological fluid that has historically been difficult to access. Access to ISF expands biological visibility, enabling new insights into human biology and a deeper understanding of biology over time. KIFFIK's platform is being advanced across drug development, diagnostics, oncology and neuroscience, with broader applications in precision medicine, AI-enabled healthcare and biological research. KIFFIK is actively seeking strategic partnerships with pharmaceutical and diagnostic companies, medical technology, digital health and AI companies, sensor developers, CROs, and leading academic and research institutions to advance and scale applications enabled by non-invasive ISF access.
A pioneer in biotechnology, Merakris Therapeutics, based in Research Triangle Park, North Carolina, is a leader in researching, developing, and marketing regenerative healthcare products. We are pioneering commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Our vision is to improve global patient care and outcomes through the pioneering and innovation of cellular regenerative biotechnologies.
Obesity care is entering a new phase—one focused not just on how much weight is lost, but on what kind of weight is lost.MS‑001 is designed precisely for this next era—delivering fat‑selective weight loss, preserving muscle health, and enhancing metabolic function to reduce cardiometabolic risk. When paired with GLP‑1 therapies, MS‑001 complements and strengthens their benefits while addressing their key limitations.
MH3D Inc. founded in 2023, headquartered in Ann Arbor, Michigan, is a medical imaging company developing next generation quantitative SPECT systems, powered by CZT detectors and advanced nuclear medicine imaging software. The company focuses on Alpha-SPECTTM platform enabling absolute quantification for theranostics across pre-clinical and future clinical applications.
Microvascular Therapeutics is a clinical-stage biotechnology company developing next-generation microbubble and nanobubble technologies that transform ultrasound from imaging into therapy. Its lead product, CardiSon™, is a superior ultrasound enhancing agent approaching NDA submission with a clear path to licensing and near-term revenue, while its therapeutic pipeline—Solv™ for treatment of microvascular obstruction in heart attack and NanoBlate™ for noninvasive tumor ablation—targets large, high-value markets with no effective existing therapies. Built on a shared platform with strong intellectual property, demonstrated validation, and a capital-efficient development strategy, MVT is positioned to generate near-term liquidity through CardiSon while advancing a
multi-billion-dollar ultrasound theranostics franchise, including partnerships with leading device companies to enable blood–brain barrier (BBB) opening and CNS drug delivery applications.
miDiagnostics is using silicon chip technology which will bring miniaturized, rapid, easy-to-use, lab-quality tests with built-in connectivity direct to the patient and clinician. Combining a nanofluidic processor on a chip and a compact reader, miDiagnostics can measure virtually any biomarker from an easily accessed sample. The Company is developing an extensive portfolio of tests for screening, diagnosis and monitoring of a wide range of health conditions, including infectious diseases. Spun out of the world-leading R&D and innovation hub in nanoelectronics and digital technologies, imec, and a research collaboration with Johns Hopkins University, the leading US research and medical centre, miDiagnostics’ goal is to enable fast, comprehensive and cost-effective health analysis, regardless of location. Based in Leuven, Belgium, miDiagnostics is a privately held company created in 2015.
Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.
Founded in 2022 and based in Shanghai, China, Neomics Pharmaceuticals is a medical technology company that focuses on the development of tumor cellular immunotherapy. The founder of the company is Wenshan Hao. The company has a technology platform for the development of new cell therapy drugs. The company's main products include a gene therapy vector micro-loop DNA synthesis method, a tumor infiltrating T-cell in vitro expansion solution, and a novel tri-generation chimeric co-stimulatory receptor-based cell therapy drug.
Neurenati Therapeutics develops a curative combination therapy to treat Hirschsprung, a rare pediatric disease, which affects 1 newborn over 5,000 live births. Today, there is no cure. A suboptimal invasive surgical procedure is the only option that patients have, to remove the non-functional section of the colon. Neurenati’s NEU-001 combination therapy could regenerate the enteric nervous system and restore bowel movement, thus sparing the patient from the surgery.
Neuromagen Pharma is a clinical stage biopharmaceutical company pioneering a novel therapeutic approach to extending healthspan by targeting one of the fundamental hallmarks of aging: the decline of telomerase activity. Its proprietary AGS/AGP compounds transiently and controllably activate Telomerase Reverse Transcriptase (TERT), an enzyme which is a root driver of biological aging. The company's lead candidate has received FDA Orphan Drug Designation for ALS, and its compounds have shown compelling preclinical efficacy across ALS, Alzheimer's, cardiovascular, metabolic, reproductive and aesthetic medicine models. Neuromagen has completed extensive IND-enabling studies with a strong safety profile and established commercial-scale manufacturing, and is now advancing toward first-in-human trials.
Novelty Nobility is developing two bispecific antibodies centered on c-Kit, a novel therapeutic target in retinal diseases. NN4101 is a preclinical, first-in-class bispecific antibody simultaneously modulating the VEGF pathway and the c-Kit/HIF-1α axis, thereby addressing multiple key pathological drivers of disease and enhancing both treatment efficacy and durability while reducing treatment burden. NN4103 is a preclinical, first-in-class bispecific antibody designed to regulate two key pathogenic drivers of geographic atrophy—choroidal mast cells and the complement cascade.
Ordaos is an AI-driven protein design company designing novel therapies and biological tools to improve human life. Our proprietary Design Engine, a proprietary lab-in-the-loop generative AI system, generates miniproteins and single-domain antibodies (VHHs) against targets that have resisted conventional discovery, and our in-house cell-free protein synthesis and biophysics labs rapidly produce and validate those designs in five days or less. The platform has been validated through partnerships with Top 5 pharma and global animal health leaders, alongside a wholly owned pipeline led by ORD-GPR75, a program directed at GPR75, a genetically validated target in obesity and addiction. Ordaos is headquartered in New York City with a satellite facility in St Paul, Minnesota.
Muscle pain and spasm are the most common problem impacting the quality of life of nearly 2+ billion people world-wide. To date there is no FDA approved Topical Muscle Relaxant. Currently available drugs like, menthol, diclofenac and Lidocaine work through counter-irritant, or anti-inflammatory or anesthetic mechanisms, respectively. However, they are only treating symptoms and do not address root cause of the pain, i.e., muscle spasms. Prima has developed first-in-class, patented PI-111 to treat muscle spasms and pain in minutes to take a lead role in $5.0+ billion market without side effects like drowsiness and headache.
Repair Biotechnologies develops the proprietary Cholesterol Degrading Platform (CDP) that clears toxic excess free cholesterol inside cells, an undruggable target that existing therapies cannot meaningfully address. Treatment dramatically and rapidly improves mitochondrial function, improves overall cell function, and reduces pathology in tissues throughout the body. Cardiovascular disease accounts for ~27% of global mortality. Current treatments slow plaque growth but cannot reverse it. Repair’s lead drugs have demonstrated 20–30% plaque regression and 100% gain in treadmill endurance in just 6 weeks in preclinical models of severe atherosclerosis, improvements that continue to grow after treatment cessation. This is the only cardiovascular treatment either developed or in development that produces functional gains of this nature.
RSP Systems technology allows for integration of a wide range of biomarkers to be tracked non-invasively
Our focus is on developing the world's first non-invasive glucose tracking device targeting FDA approval in 2029
In parallel we engage with partners to integrate our platform technology across applications within health care and electronics. RSP Systems is the the only non-invasive glucose monitoring solution that has been verified in 3rd party independent clinical studies. Our ability to transfer our algorithm or AI models to new devices so that they do not have to be personalized for individual users was featured in Nature Scientific Reports.
https://www.rspsystems.com/research/publication-in-nature-scientific-reports-calibration-and-performance-of-a-raman-based-device-for-non-invasive-glucose-monitoring-in-type-2-diabetes-3
Genomics tells you what should work. We tell you what does! At the forefront of Functional Precision Medicine, SAGE has developed a paradigm shifting technology for oncologists to identify the most effective treatment for their patients. We use genomics, NCCN guidelines, and AI to narrow down which therapies should work to then take the critical step and test on the patients real living cancer tissue which treatment do work best. We are at the forefront of Functional Precision Medicine and have developed the best-in-class functional drug profiling assay. Our technology is the only one that can create 100s of 3D microtumor replicates from a fresh tissue biopsy within 1 day and reliably test which targeted and chemotherapy treatment options with reports for oncologists and patients within 7-10 days. The test is run in a California certified clinical lab with clinically actionable results in 88% of cases.
Scioto Biosciences is a clinical-stage biotechnology company developing first-in-class therapies that harness the microbiome to address serious diseases with significant unmet medical need. The company’s lead program, SB-121, is an investigational Lactobacillus reuteri-based therapeutic designed to deliver enhanced and reproducible biological activity through Scioto’s proprietary platform. SB-121 has advanced into human clinical development, with programs focused on neurological and gastrointestinal disorders, including autism spectrum disorder and necrotizing enterocolitis. Scioto is advancing SB-121 through strategic clinical, manufacturing, and technology partnerships with the goal of translating microbiome science into scalable, clinically meaningful therapies.
SciTech Development, Inc. is a clinical-stage oncology company developing innovative cancer therapies based on its patented drug delivery technology. Its lead candidate, ST-001 nanoFenretinide™ is currently being clinically evaluated in T-cell lymphoma and Small Cell Lung Cancer. The program is designed to unlock the therapeutic potential of ST-001 using its patented nanoparticle delivery technology to improve drug delivery.
SLAM Bio’s lead program is a first-in-class ADC targeting CD84 with the opportunity to transform the treatment of blood cancers. SLM124 will enter Phase 1 clinical trials in December, with the objective of generating initial clinical data in patients with AML, MDS, CTCL, and other blood cancers where substantial unmet need remains. This represents a unique opportunity for investors to participate ahead of clinical validation and a potentially significant value inflection point. (Contact rheinick@slambio.com).
Today’s cancer therapies rely on intermittent dosing, which causes unnecessary high drug peaks and subtherapeutic troughs that allow disease to escape, alongside severe toxicities. Starton Therapeutics intends to solve this issue through controlled exposure. By maintaining optimal time-on-target to eliminate toxic spikes and sub therapeutic intervals, we aim to improve both patient outcomes and quality of life.
Stingray Therapeutics is a clinical stage biotech company focused on developing next-generation immune therapies to combat cancer. Their revolutionary approach enables the full immune system to fight back against cancer, targeting innate immunity checkpoint ENPP1 to enhance immune response and reduce tumor resistance.
A clinical-stage company, Sustained Therapeutics is developing differentiated therapeutics for underserved urologic conditions. The lead program, ST-01, is a non-opioid medication for chronic pain that is being developed to provide a month or more of pain relief from a single injection. The highly successful results of its Phase 2 trial were recently highlighted in a podium presentation at the annual conference of the American Urological Association. The company’s broader pipeline extends its platform into two additional therapeutic areas, male and female sexual health and oncology. Phase 2 trials are underway in both of these products.
Targeron Therapeutics, LLC (Targeron), an early-stage start-up biotechnology company, aims to advance the development of immunomodulators that stimulate host immunity at sites of disease. Targeron has a proprietary technology and has developed a pipeline of first-in-class biologics that combine a targeting modality with an immune-stimulatory interferon modality into a single, stable recombinant molecule. The targeting modality is a phosphatidylserine (PS)-binding domain that hones molecules to diseased cells and tissues, and the immune component is a type I (IFN-α/β)/type III (IFN-λ) interferon duet aimed at synergistically boosting host immunity at disease sites. The lead molecule under development, Gas6-IFN-β-IFN-λ, combines the actions of both types of IFNs with PS-binding Gas6 Gla-EGF domains, providing site-specific activation, multipronged immune responses, and an adjuvant effect to enhance existing immune checkpoint therapeutics such as Keytruda and Obdivo to enhance patient benefit.
TAXIS Pharmaceuticals is developing investigational therapies to combat antimicrobial resistance by targeting the very foundation of bacterial survival. Rather than relying on incremental improvements to existing antibiotic classes, our pipeline is built on novel mechanisms of action designed to dismantle the cellular machinery resistant bacteria depend on to survive and spread. TAXIS's programs span several of the CDC's highest-priority superbugs, including MRSA, drug-resistant gonorrhea, and multidrug-resistant Gram-negative infections. Our lead programs have earned QIDP designation and NIH funding, reflecting external validation of both the underlying science and the unmet medical need. Together, these programs represent a coordinated effort to restore treatment options where existing antibiotics have failed.